Cargando…

Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years: Phase II randomized controlled trial in Singapore

This was a multicenter, blinded, Phase II study (NCT00880893) conducted in Singapore. The primary objectives were to evaluate the safety of a tetravalent dengue vaccine (TDV) comprising four recombinant, live, attenuated viruses (CYD-TDV) and the dengue virus serotype-specific antibody responses bef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sin Leo, Yee, Wilder-Smith, Annelies, Archuleta, Sophia, Shek, Lynette P., Chong, Chia Yin, Nam Leong, Hoe, Yong Low, Chian, Oh, May-Lin Helen, Bouckenooghe, Alain, Wartel, T. Anh, Crevat, Denis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579907/ https://www.ncbi.nlm.nih.gov/pubmed/22894958 http://dx.doi.org/10.4161/hv.21224

Ejemplares similares

Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials
por: Tran, Ngoc Huu, et al.
Publicado: (2019)

Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis
por: Malisheni, Moffat, et al.
Publicado: (2017)

Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2–17 years: systematic review and meta-analysis
por: Rosa, Bruno Rodrigues, et al.
Publicado: (2019)

Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America
por: Forrat, Rémi, et al.
Publicado: (2021)

Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America
por: Carpp, Lindsay N., et al.
Publicado: (2020)

Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning
por: Dorigatti, I., et al.
Publicado: (2018)

Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia(®)) in Brazil; Implications for Future Pricing Considerations
por: Godói, Isabella P., et al.
Publicado: (2017)

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy
por: Rabaa, Maia A, et al.
Publicado: (2017)

Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults
por: Kirstein, Judith, et al.
Publicado: (2018)

Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial
por: Park, Juliana, et al.
Publicado: (2021)

Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data
por: Laydon, Daniel J, et al.
Publicado: (2021)

Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion of the primary series
por: Park, Juliana, et al.
Publicado: (2019)

Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial
por: Dubey, Anand Prakash, et al.
Publicado: (2015)

TDV-2215
Publicado: (1980)

TDV : noviembre 1984-noviembre 1999 /
Publicado: (2004)

CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals
por: DiazGranados, Carlos A, et al.
Publicado: (2020)

As Travel Medicine Practitioner during the SARS Outbreak in Singapore
por: Wilder-Smith, Annelies
Publicado: (2007)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico
por: Dayan, Gustavo H, et al.
Publicado: (2014)

Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands
por: El Helou, Guy, et al.
Publicado: (2020)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
por: Biswal, Shibadas, et al.
Publicado: (2021)

Cryo-EM structures of a prokaryotic heme transporter CydDC
por: Zhu, Chen, et al.
Publicado: (2023)

Immunogenicity of a novel tetravalent dengue envelope protein domain III-based antigen in mice
por: Fahimi, Hossein, et al.
Publicado: (2018)

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
por: Vigne, Claire, et al.
Publicado: (2017)

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
por: LeFevre, Inge, et al.
Publicado: (2023)

The 2003 SARS Outbreak In Singapore: Epidemiological and Clinical Features, Containment Measures, and Lessons Learned
por: Wilder-Smith, Annelies, et al.
Publicado: (2008)

Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth
por: Moyo, Nathifa, et al.
Publicado: (2020)

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials
por: Gailhardou, Sophia, et al.
Publicado: (2016)

Role of pneumococcal vaccination in prevention of pneumococcal disease among adults in Singapore
por: Eng, Philip, et al.
Publicado: (2014)

Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
por: Hannawi, Suad, et al.
Publicado: (2023)

Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005–2014)
por: L’Azou, Maïna, et al.
Publicado: (2018)

The small protein CydX is required for function of cytochrome bd oxidase in Brucella abortus
por: Sun, Yao-Hui, et al.
Publicado: (2012)

Conservation analysis of the CydX protein yields insights into small protein identification and evolution
por: Allen, Rondine J, et al.
Publicado: (2014)

Acute retroviral syndrome mimincs dengue in Singapore, a dengue endemic country
por: Tan, JH, et al.
Publicado: (2012)

Singapore’s Pandemic Preparedness: An Overview of the First Wave of COVID-19
por: Tan, Jia Bin, et al.
Publicado: (2020)

Immunogenicity and Safety of a Recombinant Tetravalent Dengue Vaccine in Children and Adolescents Ages 9–16 Years in Brazil
por: Dayan, Gustavo H., et al.
Publicado: (2013)

FGF Receptor-Mediated Gene Delivery Using Ligands Coupled to PEI-β-CyD
por: Hu, Yiping, et al.
Publicado: (2012)

Increasing Dengue Incidence in Singapore over the Past 40 Years: Population Growth, Climate and Mobility
por: Struchiner, Claudio Jose, et al.
Publicado: (2015)

Asymptomatic SARS Coronavirus Infection among Healthcare Workers, Singapore
por: Wilder-Smith, Annelies, et al.
Publicado: (2005)

Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice
por: Chiang, Chen-Yi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8aloev6c7e0c1osddpql9qdpfr